Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07313826

Treatment of Chronic Lower Back Pain With a Combination of Electrical Stimulation, LED, and Laser Therapy

This study will evaluate the impact of the Neurolumen medical device on chronic low back pain.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Naval Medical Center Portsmouth

Portsmouth, Virginia, 23708, United States

Location contact

Jeffrey Moore, MD

PRINCIPAL_INVESTIGATOR

Mary Director, Research Compliance, DVCIPM, MS, RN

CONTACT

[email protected]

3015388785

Timothy Hope Clinical Research Coordinator, BS

CONTACT

[email protected]

61905326400 ext. 2403938696

About this study

Chronic low back pain is debilitating and difficult to treat. The commercially-available Neurolumen medical device uses a combination of electrical stimulation, low-level laser, and LED therapies to treat pain. Separately, each of these treatments has shown promise for treating chronic pain. In a recent survey by the manufacturer involving over 4700 Veterans who were prescribed a Neurolumen device through their local VA facility, 93% of patients reported a reduction in pain levels, and 52% report reduction in medication, including 6% who reported cessation of all medication. Additionally, average pain levels of 7.01/10 dropped to 3.38/10 after 6 weeks of use (unpublished data). Thus, there is theoretical support and preliminary evidence for the utility of Neurolumen for treating chronic pain; yet, it is unknown whether these findings generalize to other populations. Furthermore, while a reduction in retrospective pain and medication use are promising, prospectively-collected clinical outcomes of Neurolumen use have yet to be examined. This study will examine the feasibility and efficacy of the Neurolumen devices for treating chronic lower back pain using a double-blind pilot randomized controlled trial design with a placebo/waitlist control.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosed with LBP with an average pain score of 4 or higher on DVPRS for > 3 months
  • Ability to sit or lay down for 30 minutes during treatments
  • Demonstrated ability to correctly use the device and maintain adequate sensor contact throughout (assisted or unassisted)
  • Female participants who could possibly become pregnant must agree to use a highly effective contraceptive method from the screening period through the 4 weeks of study intervention and any use during the wait-list control period. These methods include a physical barrier method (e.g., condom) plus an additional hormonal, IUD, tubal ligation, or second type of barrier (e.g., diaphragm). In addition, they must abstain from egg collection or donation during the same period.

Exclusion criteria

  • Individuals < 18 or >70 years of age at enrollment
  • Persons with Pacemakers, or interstitial pumps, or spinal cord stimulator in ON mode.
  • Persons who have received back surgery (open) within the last 3 months
  • Pregnant or sexually active female subjects who could possibly become pregnant and who are not willing to use an acceptable form of contraception (barrier method plus one of the following: second barrier, hormonal, IUD, or tubal ligation).

Treatment and study plan

Active Neurolumen

Device

Neurolumen has been cleared by the FDA for the treatment of pain (FDA: 142025) and utilizes a combination of low-level lasers, Light-Emitting Diodes, and electrical stimulation over a 30-minute treatment period to target inflammation and circulation to the affected area. Participants will use the device daily for 4 weeks.

Inactive Neurolumen

Device

The sham Neurolumen device will look the same an the Active Neurolumen, and will appear to turn on, but will not provide any treatment

Primary outcomes

  1. Pain Intensity

    Time frame: Weeks 1-12

    Defense and Veterans Pain Rating Scale. On a scale of 0-10, with higher scores denoting more pain.

  2. Pain Medication Use

    Time frame: Weeks 1-12

    Opioid Use Diary

Secondary outcomes

  1. Physical Function

    Time frame: Weeks 1-12

    Patient-Reported Outcomes Measurement Information System (PROMIS) -29 Adult Profile 2.0 Instrument, Physical Function subscale.

    Each item is scored on a scale 1-5, with 1=without any difficulty and 5=unable to do. Items will be summed and t-scored (0-100)

  2. Sleep Disturbance

    Time frame: Weeks 1-12

    Patient-Reported Outcomes Measurement Information System (PROMIS) -29 Adult Profile 2.0 Instrument, Sleep Disturbance subscale. Each item is scored on a scale 1-5, with 1=not at all and 5=very much. Items will be summed and t-scored (0-100), with higher scores denoting more sleep disturbance.

Other outcomes

  1. Pain Catastrophizing

    Time frame: Weeks 1-12

    University of Washington Concerns About Pain Six Item Short Form (UW-CAP SF-6). Each item is scored on a scale of 1-5, with 1=never and 5=always. Items are summed and t-scored (0-100), with higher scores denoting more pain catastrophizing.

  2. Perceived Efficacy

    Time frame: Weeks 1-12

    Patient Global Impression of Change Scale (PGIC). Each item is scored on a scale 1-5, with 1=very much improved and 7= Very much worse. Items will be summed and t-scored (0-100), with higher scores denoting more negative change.

Study contacts

Contact information is provided by the study sponsor or research team.

Director, Research Administration DVCIPM

CONTACT

[email protected]

301-400-4242

Sponsors and collaborators

Lead sponsor

Defense and Veterans Center for Integrative Pain Management

Other

Collaborators

  • Neurolumen LLC

Registry information

Official study title

Neurolumen for Chronic Lower Back Pain: A Pilot RCT Study

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jan 2, 2026
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.